| scholarly article | Q13442814 |
| P2093 | author name string | G Pedersen | |
| J Brynskov | |||
| T Kirkegaard | |||
| T Saermark | |||
| P2860 | cites work | Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha | Q24319999 |
| Expression of functional CXCR4 chemokine receptors on human colonic epithelial cells | Q24563114 | ||
| Tumour necrosis factor alpha converting enzyme (TACE) activity in the colonic mucosa of patients with inflammatory bowel disease | Q24669999 | ||
| A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells | Q28119154 | ||
| Protein kinase C-dependent alpha-secretase competes with beta-secretase for cleavage of amyloid-beta precursor protein in the trans-golgi network | Q28143129 | ||
| ADAM family proteins in the immune system | Q28198038 | ||
| Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial | Q28202504 | ||
| Role of tumor necrosis factor receptor 2 (TNFR2) in colonic epithelial hyperplasia and chronic intestinal inflammation in mice | Q30793383 | ||
| A simple method to establish short-term cultures of normal human colonic epithelial cells from endoscopic biopsy specimens. Comparison of isolation methods, assessment of viability and metabolic activity | Q30917519 | ||
| Adamalysins. A family of metzincins including TNF-alpha converting enzyme (TACE). | Q33692956 | ||
| Infliximab for the treatment of fistulas in patients with Crohn's disease | Q33860666 | ||
| Tumor necrosis factor: biology and therapeutic inhibitors | Q34065153 | ||
| A distinct array of proinflammatory cytokines is expressed in human colon epithelial cells in response to bacterial invasion | Q34192675 | ||
| TACE and other ADAM proteases as targets for drug discovery | Q34218091 | ||
| Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease | Q34377789 | ||
| Small therapeutic molecules for the treatment of inflammatory bowel disease | Q34600992 | ||
| Interferon gamma induces differential upregulation of alpha and beta chemokine secretion in colonic epithelial cell lines | Q35349234 | ||
| Recent advances in inhibitors of matrix metalloproteinases for cancer therapy | Q36255869 | ||
| Stimulation-induced down-regulation of tumor necrosis factor-alpha converting enzyme | Q40881822 | ||
| Intracellular maturation and localization of the tumour necrosis factor alpha convertase (TACE) | Q40892360 | ||
| Cutting edge: a dominant negative form of TNF-alpha converting enzyme inhibits proTNF and TNFRII secretion. | Q40925017 | ||
| Expression, function and regulation of the intercellular adhesion molecule-1 (ICAM-1) on human intestinal epithelial cell lines | Q41135170 | ||
| Expression of class II molecules on intestinal epithelial cells in humans. Differences between normal and inflammatory bowel disease | Q41702404 | ||
| Incidence and prevalence of Crohn's disease in the county of Copenhagen, 1962-87: a sixfold increase in incidence | Q41851215 | ||
| A place for TACE. | Q41894206 | ||
| Differential and regulated expression of C-X-C, C-C, and C-chemokines by human colon epithelial cells | Q44634002 | ||
| Treatment of ulcerative colitis with an engineered human anti-TNFalpha antibody CDP571. | Q47847779 | ||
| Alteration of gene expression by intestinal epithelial cells precedes colitis in interleukin-2-deficient mice. | Q52529883 | ||
| Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. | Q53540951 | ||
| A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. | Q53964227 | ||
| Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis. | Q54110885 | ||
| Tumour necrosis factor α and interleukin 1β in relapse of Crohn's disease | Q57569294 | ||
| Tumour necrosis factor-alpha and interferon-gamma production measured at the single cell level in normal and inflamed human intestine | Q68350435 | ||
| Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease | Q70489716 | ||
| Course of ulcerative colitis: analysis of changes in disease activity over years | Q72036054 | ||
| Tumor necrosis factor alpha-producing cells in the intestinal mucosa of children with inflammatory bowel disease | Q72462916 | ||
| The effect of a metalloproteinase inhibitor (GI5402) on tumor necrosis factor-alpha (TNF-alpha) and TNF-alpha receptors during human endotoxemia | Q73023294 | ||
| Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease | Q73107122 | ||
| Expression of tumor necrosis factor-alpha in cultured human endothelial cells stimulated with lipopolysaccharide or interleukin-1alpha | Q73435148 | ||
| Cultures of human colonic epithelial cells isolated from endoscopical biopsies from patients with inflammatory bowel disease. Effect of IFNgamma, TNFalpha and IL-1beta on viability, butyrate oxidation and IL-8 secretion | Q73470124 | ||
| An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial | Q73785104 | ||
| Inhibition of tumor necrosis factor-alpha (TNF-alpha) production and arthritis in the rat by GW3333, a dual inhibitor of TNF-alpha-converting enzyme and matrix metalloproteinases | Q74372061 | ||
| Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial | Q77374966 | ||
| An essential role for ectodomain shedding in mammalian development | Q77544828 | ||
| TNF-alpha-converting enzyme activity in colonic biopsy specimens from patients with inflammatory bowel disease revealed by mRNA and in vitro assay | Q78027487 | ||
| P433 | issue | 1 | |
| P921 | main subject | TNF | Q18032037 |
| P304 | page(s) | 146-153 | |
| P577 | publication date | 2004-01-01 | |
| P1433 | published in | Clinical and Experimental Immunology | Q15716708 |
| P1476 | title | Tumour necrosis factor-alpha converting enzyme (TACE) activity in human colonic epithelial cells | |
| P478 | volume | 135 |
| Q37052477 | ADAM Proteases and Gastrointestinal Function |
| Q33455297 | AMP-activated protein kinase confers protection against TNF-{alpha}-induced cardiac cell death |
| Q39773760 | Efficacy of Omega Fatty Acid Supplementation on mRNA Expression Level of Tumor Necrosis Factor Alpha in Patients with Gastric Adenocarcinoma |
| Q34136570 | Identification of matrix metalloproteinase-2 and -9 activities within intestinal mucosa of clinically healthy beagle dogs |
| Q50113156 | Macrocyclic θ-defensins suppress tumor necrosis factor-α (TNF-α) shedding by inhibition of TNF-α converting enzyme |
| Q37100247 | Matrix metalloproteinase-9-mediated tissue injury overrides the protective effect of matrix metalloproteinase-2 during colitis |
| Q34626040 | Mechanisms of disease: protease functions in intestinal mucosal pathobiology |
| Q28565754 | Metalloprotease disintegrin-mediated ectodomain shedding of EGFR ligands promotes intestinal epithelial restitution |
| Q39896496 | Spontaneous and cytokine induced expression and activity of matrix metalloproteinases in human colonic epithelium |
| Q33851440 | TACE/ADAM-17 phosphorylation by PKC-epsilon mediates premalignant changes in tobacco smoke-exposed lung cells |
| Q39276410 | The EGF receptor and HER2 participate in TNF-α-dependent MAPK activation and IL-8 secretion in intestinal epithelial cells |
| Q46358054 | Tumor Necrosis Factor-Alpha: Role in Development of Insulin Resistance and Pathogenesis of Type 2 Diabetes Mellitus |
Search more.